Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
LEGN Legend Biotech
51.605+1.475+2.94%
Trading Session
01/31 11:38 ET
High
52.060
Open
50.260
Turnover
7.95M
Low
50.260
Pre Close
50.130
Volume
155.72K
Intraday
5D
1D
1W
1M
1Q
1Y
Price Forecast
News
Comment
UBS Adjusts Legend Biotech's Price Target to $76 From $66, Maintains Buy Rating
10:01 AM EST, 01/30/2023 (MT Newswires) -- (MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may co
Analysts Offer Insights on Healthcare Companies: Argenx Se (ARGX) and Legend Biotech (LEGN)
Legend Biotech (NASDAQ:LEGN) Shares Gap Up to $53.84
Legend Biotech Co. (NASDAQ:LEGN – Get Rating)'s stock price gapped up prior to trading on Friday . The stock had previously closed at $53.84, but opened at $55.04. Legend Biotech shares last traded a
Barclays Boosts Legend Biotech (NASDAQ:LEGN) Price Target to $65.00
Legend Biotech (NASDAQ:LEGN – Get Rating) had its target price raised by Barclays from $53.00 to $65.00 in a report released on Wednesday, The Fly reports. They currently have an overweight rating on
Brokers Offer Predictions for Legend Biotech Co.'s Q1 2023 Earnings (NASDAQ:LEGN)
Legend Biotech Co. (NASDAQ:LEGN – Get Rating) – Stock analysts at Jefferies Financial Group issued their Q1 2023 EPS estimates for shares of Legend Biotech in a research report issued on Tuesday,
BTIG Sees Legend Commercializing Carvykti in Earlier Lines After Study Hits Goal
Piper Keeps $78 Target on Legend Biotech After Carvykti Trial Hits
Legend Biotech Says Phase 3 Trial of Multiple Myeloma Drug Candidate Meets Primary Endpoint; Shares Rise
09:24 AM EST, 01/27/2023 (MT Newswires) -- Legend Biotech (LEGN) said Friday its phase 3 trial of Carvykti in adult patients with relapsed and lenalidomide-refractory multiple myeloma met its primary
JNJ/ Legend CAR-T Therapy Succeeds in Phase 3 Multiple Myeloma Trial
Legend Biotech Phase 3 Study of Carvykti Meets Primary Endpoint
By Robb M. Stewart Legend Biotech Corp. said Friday its late-stage study of a treatment for adult patients with relapsed and lenalidomide-refractory multiple myeloma met its main target. The biotech
Company Overview
More
Legend Biotech Corp. is a holding company, which engages in the discovery and development of novel cell therapies for oncology and other indications. It operates through the North America and China geographical segments. The company was founded on May 27, 2015 and is headquartered in Somerset, NJ.
CEO： Dr. Ying Huang, PhD
Market： NASDAQ
Listing Date： 06/05/2020
Paper Trade
More
Hot List
TradeSearchNews
SymbolLatest price%Chg
Loading...
Watchlist
No Stock Yet